252 related articles for article (PubMed ID: 18829501)
1. N-(2,6-dimethoxypyridine-3-yl)-9-methylcarbazole-3-sulfonamide as a novel tubulin ligand against human cancer.
Wang YM; Hu LX; Liu ZM; You XF; Zhang SH; Qu JR; Li ZR; Li Y; Kong WJ; He HW; Shao RG; Zhang LR; Peng ZG; Boykin DW; Jiang JD
Clin Cancer Res; 2008 Oct; 14(19):6218-27. PubMed ID: 18829501
[TBL] [Abstract][Full Text] [Related]
2. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.
Liou JP; Hsu KS; Kuo CC; Chang CY; Chang JY
J Pharmacol Exp Ther; 2007 Oct; 323(1):398-405. PubMed ID: 17660383
[TBL] [Abstract][Full Text] [Related]
3. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
Kuo CC; Hsieh HP; Pan WY; Chen CP; Liou JP; Lee SJ; Chang YL; Chen LT; Chen CT; Chang JY
Cancer Res; 2004 Jul; 64(13):4621-8. PubMed ID: 15231674
[TBL] [Abstract][Full Text] [Related]
4. Double blockade of cell cycle at g(1)-s transition and m phase by 3-iodoacetamido benzoyl ethyl ester, a new type of tubulin ligand.
Jiang JD; Denner L; Ling YH; Li JN; Davis A; Wang Y; Li Y; Roboz J; Wang LG; Perez-Soler R; Marcelli M; Bekesi G; Holland JF
Cancer Res; 2002 Nov; 62(21):6080-8. PubMed ID: 12414632
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structure-activity relationships of carbazole sulfonamides as a novel class of antimitotic agents against solid tumors.
Hu L; Li ZR; Li Y; Qu J; Ling YH; Jiang JD; Boykin DW
J Med Chem; 2006 Oct; 49(21):6273-82. PubMed ID: 17034133
[TBL] [Abstract][Full Text] [Related]
6. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
Wong VK; Chiu P; Chung SS; Chow LM; Zhao YZ; Yang BB; Ko BC
Clin Cancer Res; 2005 Aug; 11(16):6002-11. PubMed ID: 16115945
[TBL] [Abstract][Full Text] [Related]
7. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K
Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285
[TBL] [Abstract][Full Text] [Related]
8. Novel pyridinyl and pyrimidinylcarbazole sulfonamides as antiproliferative agents.
Hu L; Li ZR; Wang YM; Wu Y; Jiang JD; Boykin DW
Bioorg Med Chem Lett; 2007 Mar; 17(5):1193-6. PubMed ID: 17197178
[TBL] [Abstract][Full Text] [Related]
9. The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-alpha production with antitumor activity.
Zhang LH; Wu L; Raymon HK; Chen RS; Corral L; Shirley MA; Narla RK; Gamez J; Muller GW; Stirling DI; Bartlett JB; Schafer PH; Payvandi F
Cancer Res; 2006 Jan; 66(2):951-9. PubMed ID: 16424030
[TBL] [Abstract][Full Text] [Related]
10. Tricyclic pyrone analogs: a new synthetic class of bifunctional anticancer drugs that inhibit nucleoside transport, microtubule assembly, the viability of leukemic cells in vitro and the growth of solid tumors in vivo.
Perchellet EM; Ladesich JB; Magill MJ; Chen Y; Hua DH; Perchellet JP
Anticancer Drugs; 1999 Jun; 10(5):489-504. PubMed ID: 10477169
[TBL] [Abstract][Full Text] [Related]
11. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
[TBL] [Abstract][Full Text] [Related]
12. Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk1-involved signaling pathways.
Chen YC; Lu PH; Pan SL; Teng CM; Kuo SC; Lin TP; Ho YF; Huang YC; Guh JH
Biochem Pharmacol; 2007 Jun; 74(1):10-9. PubMed ID: 17475221
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin.
Yoshimatsu K; Yamaguchi A; Yoshino H; Koyanagi N; Kitoh K
Cancer Res; 1997 Aug; 57(15):3208-13. PubMed ID: 9242451
[TBL] [Abstract][Full Text] [Related]
14. TTI-237: a novel microtubule-active compound with in vivo antitumor activity.
Beyer CF; Zhang N; Hernandez R; Vitale D; Lucas J; Nguyen T; Discafani C; Ayral-Kaloustian S; Gibbons JJ
Cancer Res; 2008 Apr; 68(7):2292-300. PubMed ID: 18381436
[TBL] [Abstract][Full Text] [Related]
15. STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells.
Newman SP; Foster PA; Stengel C; Day JM; Ho YT; Judde JG; Lassalle M; Prevost G; Leese MP; Potter BV; Reed MJ; Purohit A
Clin Cancer Res; 2008 Jan; 14(2):597-606. PubMed ID: 18223236
[TBL] [Abstract][Full Text] [Related]
16. Benzoylurea derivatives as a novel class of antimitotic agents: synthesis, anticancer activity, and structure-activity relationships.
Song DQ; Wang Y; Wu LZ; Yang P; Wang YM; Gao LM; Li Y; Qu JR; Wang YH; Li YH; Du NN; Han YX; Zhang ZP; Jiang JD
J Med Chem; 2008 Jun; 51(11):3094-103. PubMed ID: 18457382
[TBL] [Abstract][Full Text] [Related]
17. Biological evaluation on different human cancer cell lines of novel colchicine analogs.
De Vincenzo R; Ferlini C; Distefano M; Gaggini C; Riva A; Bombardelli E; Morazzoni P; Danieli B; Capelli G; Mancuso S; Scambia G
Oncol Res; 1999; 11(3):145-52. PubMed ID: 10527074
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
19. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps.
Kasibhatla S; Baichwal V; Cai SX; Roth B; Skvortsova I; Skvortsov S; Lukas P; English NM; Sirisoma N; Drewe J; Pervin A; Tseng B; Carlson RO; Pleiman CM
Cancer Res; 2007 Jun; 67(12):5865-71. PubMed ID: 17575155
[TBL] [Abstract][Full Text] [Related]
20. R-253 disrupts microtubule networks in multiple tumor cell lines.
Gururaja TL; Goff D; Kinoshita T; Goldstein E; Yung S; McLaughlin J; Pali E; Huang J; Singh R; Daniel-Issakani S; Hitoshi Y; Cooper RD; Payan DG
Clin Cancer Res; 2006 Jun; 12(12):3831-42. PubMed ID: 16778111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
